Search by Medical Condition

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Clinical Trials for Ependymoma

• PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications
• B7-H3-CAR T Cells for Pediatric CNS Tumors
• Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors or Meningiomas Expressing SST2A
• Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer
• Combination Intraventricular Chemotherapy Pilot Study: 5-Azacytidine (5-AZA) and Trastuzumab Infusions Into the Fourth Ventricle or Resection Cavity in Children and Adults With Recurrent or Residual Posterior Fossa Ependymoma
• 131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma
• ONC206 for Treatment of Newly Diagnosed, or Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant Brain Tumors (PNOC 023)
• Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms
• Chemotherapy and Donor Stem Transplant for the Treatment of Patients With High Grade Brain Cancer
• Study of the Effect of GM-CSF on Macrophages in Ependymoma
• Innovative Trial for Understanding the Impact of Targeted Therapies in NF2
• Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial
• Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial
• Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial)
• Pediatric Trial of Indoximod With Chemotherapy and Radiation for Relapsed Brain Tumors or Newly Diagnosed DIPG
• StrataXRT in Preventing Radiation Dermatitis in Pediatric Patients Undergoing Radiation Therapy to the Brain or Spinal Cord
• Marizomib for Recurrent Low-Grade and Anaplastic Supratentorial, Infratentorial, and Spinal Cord Ependymoma
• Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)
• Infusion of 5-Azacytidine (5-AZA) Into the Fourth Ventricle in Patients With Recurrent Posterior Fossa Ependymoma
• Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)
• SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors
• Ribociclib and Everolimus in Treating Children With Recurrent or Refractory Malignant Brain Tumors
• Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)
• Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)
• Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)
• Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)
• Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)
• Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
• Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
• COZMOS:Phase I/Ib Trial of Combined 5'Azacitidine and Carboplatin for Recurrent/Refractory Pediatric Brain/Solid Tumors
• Memantine for Prevention of Cognitive Late Effects in Pediatric Patients Receiving Cranial Radiation Therapy for Localized Brain Tumors
• Immune Checkpoint Inhibitor Nivolumab in People With Recurrent Select Rare CNS Cancers
• Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
• A Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2
• Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors
• Autologous Stem Cell Collection and Reinfusion in Newly Diagnosed High Grade Gliomas
• Gadobutrol Versus Gadopentetate Dimeglumine or Gadobenate Dimeglumine Before DCE-MRI in Diagnosing Patients With Multiple Sclerosis, Grade II-IV Glioma, or Brain Metastases
• Infusion of 5-Azacytidine (5-AZA) Into the Fourth Ventricle in Children With Recurrent Posterior Fossa Ependymoma
• Pilot Study of the Effect of Trastuzumab and GM-CSF on Children With Recurrent Ependymoma
• Erlotinib in Combination With Temozolomide in Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors
• Phase II Study of Intraventricular Methotrexate in Children With Recurrent or Progressive Malignant Brain Tumors
• Phase II Pediatric Study With Dabrafenib in Combination With Trametinib in Patients With HGG and LGG
• Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primary Malignant Brain Tumors
• An International Clinical Program for the Diagnosis and Treatment of Children With Ependymoma
• Alisertib and Fractionated Stereotactic Radiosurgery in Treating Patients With Recurrent High Grade Gliomas
• 18F-FDOPA PET/CT or PET/MRI in Measuring Tumors in Patients With Newly-Diagnosed or Recurrent Gliomas
• Everolimus for Children With Recurrent or Progressive Ependymoma
• A Trial of Surgery and Fractionated Re-Irradiation for Recurrent Ependymoma
• Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma
• 3T MRI Biomarkers of Glioma Treatment Response
• Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors
• Immunotherapy for Recurrent Ependymomas in Children Using Tumor Antigen Peptides With Imiquimod
• Phase I/II Trial of Safety and Anti-tumor Efficacy of AXL1717(Picropodophyllin) in the Treatment of Recurrent Malignant Astrocytomas
• Phase I Study of 5-Fluorouracil in Children and Young Adults With Recurrent Ependymoma
• Efficacy of Hypofractionated XRT w/Bev. + Temozolomide for Recurrent Gliomas
• Sunitinib Malate in Treating Younger Patients With Recurrent, Refractory, or Progressive Malignant Glioma or Ependymoma
• Antiangiogenic Therapy for Children With Recurrent Medulloblastoma, Ependymoma and ATRT
• Aflac ST0901 CHOANOME - Sirolimus in Solid Tumors
• Carboplatin and Bevacizumab for Recurrent Ependymoma
• Single-agent Erlotinib in Patients Previously Treated With Oral Etoposide in Protocol OSI-774-205
• Bafetinib in Treating Patients With Recurrent High-Grade Glioma or Brain Metastases
• Vaccination With Dendritic Cells Loaded With Brain Tumor Stem Cells for Progressive Malignant Brain Tumor
• Fluorine F 18 Fluorodopa-Labeled PET Scan in Planning Surgery and Radiation Therapy in Treating Patients With Newly Diagnosed High- or Low-Grade Malignant Glioma
• Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors
• RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma
• Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Ependymoma
• Ritonavir and Lopinavir in Treating Patients With Progressive or Recurrent High-Grade Glioma
• Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia
• Carboplatin as a Radiosensitizer in Treating Childhood Ependymoma
• Vorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spinal Cord Tumors
• Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma
• Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma
• A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors
• ABT-888 and Temozolomide in Treating Young Patients With Recurrent or Refractory CNS Tumors
• Bevacizumab and Lapatinib in Children With Recurrent or Refractory Ependymoma
• Methionine PET/CT Studies In Patients With Cancer
• Dose-Dense Temozolomide + Lapatinib for Recurrent Ependymoma
• Therapy Optimization Trial for the Treatment of Relapsed or Refractory Brain Tumors in Children
• Observing Young Patients With Ependymoma Undergoing Standard Combination Chemotherapy
• Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagnosed or Relapsed Solid Tumor
• A Phase I Study of AdV-tk + Prodrug Therapy in Combination With Radiation Therapy for Pediatric Brain Tumors
• Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma
• A Study of Pemetrexed in Children With Recurrent Cancer
• Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer
• Use of EF5 to Measure the Oxygen Level in Tumor Cells of Patients Undergoing Surgery or Biopsy for Newly Diagnosed Supratentorial Malignant Glioma
• Bevacizumab and Irinotecan in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade Glioma
• Ispinesib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Lymphoma
• AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors
• Radiation Therapy and Combination Chemotherapy in Treating Young Patients With Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Ependymoma
• High-Dose Methotrexate in Treating Young Patients With Residual Ependymoma
• Etoposide in Treating Young Patients With Relapsed Ependymoma
• Positron Emission Tomography Using Fluorine F 18 EF5 to Find Oxygen in Tumor Cells of Patients Who Are Undergoing Surgery or Biopsy for Newly Diagnosed Brain Tumors
• Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas
• Lenalidomide in Treating Young Patients With Recurrent, Progressive, or Refractory CNS Tumors
• Lapatinib in Treating Young Patients With Recurrent or Refractory Central Nervous System Tumors
• Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment
• Erlotinib and Temozolomide in Treating Young Patients With Recurrent or Refractory Solid Tumors
• Cilengitide in Treating Children With Refractory Primary Brain Tumors
• FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or Leukemia
• Temozolomide and O6-Benzylguanine in Treating Children With Recurrent Brain Tumors
• Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction
• Observation or Radiation Therapy and/or Chemotherapy and Second Surgery in Treating Children Who Have Undergone Surgery for Ependymoma
• Flavopiridol in Treating Children With Relapsed or Refractory Solid Tumors or Lymphomas
• Thiotepa Followed by Peripheral Stem Cell or Bone Marrow Transplant in Treating Patients With Malignant Glioma
• Combination Chemotherapy Followed by Radiation Therapy in Treating Patients With Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Ependymoma
• Combination Chemotherapy Followed by Radiation Therapy in Treating Children With Localized Ependymoma
• Irinotecan in Treating Children With Refractory Solid Tumors
• Antineoplaston Therapy in Treating Patients With Ependymoma
• Combination Chemotherapy Plus Radiation Therapy in Treating Adult Patients With Brain Cancer
• Etoposide Plus Cisplatin in Treating Patients With Recurrent Ependymomas